Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Corporate Update (September 2017)
24 slides from Genocea Biosciences's corporate update, Sep 27, 2017
Slide 1: Company Update September 2017
Company Update September 2017 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or ass
Slide 3: Exploring Strategic Alternatives for GEN-003
• Positive 12-month Phase 2b data did not lead to a pathway for Genocea to independently advance GEN-003 given time and cost of Phase 3 trials – Workforce reduction reflects this • Strategic process underway to seek to maximize value for GEN- 003 through sale, partnership etc. • Continue to believe
Slide 4: Leadership in Neoantigen Cancer Vaccines
Leadership in Neoantigen Cancer Vaccines
Slide 5: Mission and vision: curing cancer with next-generation cancer vaccines
• Our mission: to create breakthrough vaccines based on the right antigens 5 Our vision: Curing cancer with next-generation cancer vaccines ATLAS™ Unique, proven platform for neoantigen selection Proven team of vaccine experts Outstanding Board and Scientific Advisors Efficacious cancer vaccines
Slide 6: Neoantigens are an exciting new target class in immuno-oncology
Neoantigens are an exciting new target class in immuno-oncology 6 • Personalized tumor mutations (neoantigens) are “foreign” to immune system Schumacher, Schreiber, 2015 Ott, Sahin, 2017 • Response to neoantigens drives checkpoint inhibitor (CPI) efficacy • Possible to vaccinate against neoantigens
Slide 7: Neoantigen vaccines represent a next wave of personalized cancer immunotherapy
• Complementary MoA: “steering wheel” once brakes are off • Well tolerated1,2 • Applicable to most cancer types 7 After CAR-T therapy, neoantigen vaccines represent a next wave of personalized cancer immunotherapy Potential synergy with CPI Opportunity to benefit millions Disease + Good PS All Patie
Slide 8: Neoantigen Selection Crucial to Vaccine Success
Neoantigen Selection Crucial to Vaccine Success 8
Slide 9: Cancer biology creates significant antigen selection challenges
9 Cancer biology creates significant antigen selection challenges Tumor mutational burden by cancer type Up to thousands of candidate antigens per patient
Slide 10: Conventional predictive approaches have limitations
10 Thought leaders agree: conventional predictive approaches have limitations You can algorithm till the cows come home and you’re not really going to know if you’re improving things ~Drew Pardoll Nature, 2016 The truth is…that current neoepitope prediction algorithms return a vast number of candida
Slide 11: Conventional approaches yield limited immune responses
*Cohort level; number of SLP with responses in all patients/total SLP immunized across all patients **Presumed CD4 (total PBMC). Text states majority of responses were CD4 but not disclosed in figure. 11 Conventional approaches yield limited immune responses regardless of delivery system/modality %
Slide 12: ATLAS uses patients' own T cells to identify true neoantigens
12 ATLAS platform uses biology – patients’ own T cells – to identify true neoantigens Patient- specific HLA agnostic CD4+ & CD8+ antigens Hot and cold tumors *For CD4+ T cell screening the cLLO is not co- expressed, resulting in conventional endosomal processing and presentation by MHC cII Input: Ev
Slide 13: ATLAS data supports superiority in neoantigen identification
• Not all neoantigens are “good” • CD4+ and CD8 + antigens are not the same • No association with key algorithm inputs: – Binding affinity – RNA expression – Allele frequency – Frame shifts 13 ATLAS data supports superiority in neoantigen identification; exposes flaws in predictive approaches * CD8+
Slide 14: Prioritizing neoantigens with pre-existing T cell responses
14 Prioritizing neoantigens with pre-existing T cell responses may increase probability of protective vaccination Tumor-specific mutations ATLAS output: IFN-gamma pre-treatment responses CD4+ CD8+ Actual neoantigens Pre-existing immunity associated with effective vaccination: • Malignant glioma1 • H
Slide 15: ATLAS: Don't Guess. Know.
15 ATLAS: Don’t Guess. Know. ATLAST cell antigen T cell Tumor Cell
Slide 16: Neoantigen vaccine program GEN-009
Neoantigen vaccine program GEN-009 16
Slide 17: ATLAS neoantigen selection drives personalized cancer vaccine program
Collect tumor and blood samples, sequence exome ATLAS to identify true neoantigens of CD4+ and CD8+ T cell responses Synthesize vaccine with ATLAS-identified T cell antigens Ship personalized product to clinical site ATLAS neoantigen selection drives potential best-in-class personalized cancer vacci
Slide 18: Clinical program designed to demonstrate superiority of ATLAS
• First-in-man study overview: – Monotherapy then combination with CPI therapy – Objectives: safety & immunogenicity – Multiple tumor types – Patient cohort: No evidence of disease, high risk of relapse – Expands to test dose regimens Planned Milestones • IND: Q1 2018 • Initial monotherapy immunogen
Slide 19: Investment Opportunity
Investment Opportunity 19
Slide 20: Neoantigen cancer vaccine pipeline drives multiple potential milestones
20 Neoantigen cancer vaccine pipeline drives multiple potential milestones in next 18 months DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 STATUS & EXPECTED MILESTONES GEN-009 1st Generation Neoantigen Cancer Vaccine • Peptide + adjuvant vaccine • IND filing in Q1 2018 • Immunogenicity data in H1 2019 GEN-
Slide 21: Strong science
• SAB – Elizabeth Jaffee, MD, Johns Hopkins, Deputy Director Sidney Kimmel Comprehensive Cancer Center • President, AACR; Chair, NCI Moonshot – Chuck Drake, MD, PhD, Columbia, Director of Genitourinary Oncology and Associate Director for Clinical Research – Luis Diaz, MD, MSKCC, Head of Division of
Slide 22: Creating the leading next-generation cancer vaccine company
• Compelling role for effective neoantigen vaccines in the I-O revolution • Genocea brings differentiated vaccine technology to bear to create best-in-class vaccines • Important milestones delivered over next 2 years • Strong science, proven team 22 We are creating the leading next-generation cancer
Slide 23: Financial summary
• Cash at Q2 2017 – $35.2m • $49m ATM facility capacity • Debt facility – $15.8m outstanding • Funded into middle of 2018 • Shares outstanding (08/07/17) – Basic – 28.7m – Fully diluted – 33.5m • Exploring strategic alternatives for GEN-003 – Phase 3-ready genital herpes immunotherapy 23 Financial s
Slide 24: Genocea Biosciences, Inc. contact details
Genocea Biosciences, Inc. NASDAQ: GNCA Cambridge Discovery Park 100 Acorn Park Drive 5th floor Cambridge, MA 02140 USA Phone: +1 617.876.8191 www.genocea.com 24
Genocea Biosciences — Corporate Update (September 2017) on 6ix